France Recombinant Protein Therapeutics Cdmo Market Size & Outlook
France recombinant protein therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
France recombinant protein therapeutics cdmo market highlights
- The France recombinant protein therapeutics cdmo market generated a revenue of USD 914.2 million in 2023 and is expected to reach USD 2,260.0 million by 2030.
- The France market is expected to grow at a CAGR of 13.8% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
Recombinant protein therapeutics cdmo market data book summary
| Market revenue in 2023 | USD 914.2 million |
| Market revenue in 2030 | USD 2,260.0 million |
| Growth rate | 13.8% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, France accounted for 4.4% of the global recombinant protein therapeutics cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK recombinant protein therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 2,892.8 million by 2030.
Interferons was the largest segment with a revenue share of 21.45% in 2023. Horizon Databook has segmented the France recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
The French pharmaceutical industry is a technology-driven, innovative, and densely populated industry with high levels of technological & logistical expertise. The biopharmaceutical services industry in the country has benefited from the recent trends in the biopharmaceutical landscape, as many manufacturers have divested their clinical research, development, and manufacturing with new technology & manufacturing facilities.
Furthermore, key initiatives undertaken by the companies are expected to drive the market growth in the country. For instance, in October 2023, LFB Biomanufacturing, a subsidiary of the LFB Group specializing in the production of therapeutic proteins through cell culture, is initiating a project to enhance its bioproduction capacity.
The endeavor is backed by funding from the “France 2030” plan. This strategic initiative for LFB aims to double the industrial capacities of its Ales site, consequently boosting the bioproduction of innovative therapies in France.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
France recombinant protein therapeutics cdmo market size, by type, 2018-2030 (US$M)
France Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
